Tonix Pharmaceuticals saw its shares swing wildly between gains and losses on Wednesday morning as they started to trade ...

Tonix Pharmaceuticals has reported positive topline outcomes from its Phase I single ascending dose study of its ...

Tonix shares are moving higher on Friday after the company provided preliminary 2024 fiscal-year financial results.

Research analysts at StockNews.com initiated coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) in a research note issued to investors on Monday. The brokerage set a “sell” ...

Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first quarter of ...

Tonix Pharmaceuticals (TNXP) stock jumped 11% Friday after the company issued a business update along with a preliminary 2024 ...

Tonix Pharmaceuticals (TNXP) stock plunged after the company carried out a 1-for-100 reverse stock split as it awaits approval for its ...

Tonix Pharmaceuticals Holding Corp. announced positive results from a Phase 1 trial of its investigational drug TNX-1500, a monoclonal antibody targeting CD40L, aimed at preventing kidney ...

Tonix Pharmaceuticals has a beta of 2.02, meaning that its share price is 102% more volatile than the S&P 500. Comparatively, Annexon has a beta of 1.11, meaning that its share price is 11% more ...

CHATHAM, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a ...